Tag:

Parexel International

Latest Headlines

Latest Headlines

Parexel eyes the Middle East with its latest CRO buyout

Parexel International is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.

Parexel expects to hit the $2B mark in fiscal 2015

Parexel figures it can rake in more than $2 billion in revenue in the next fiscal year, banking on a solid book-to-bill ratio and increasing global demand to deliver an all-time high.

Parexel rolls out new eClinical tech to speed up study start-up

Parexel International has reformatted its clinical trial management software, streamlining its services with an update the company believes can help its clients start studies faster.

Tech vendors flock to DIA to show off new software

With the clinical trial community gathering over the past week in San Diego for DIA 2014, eClinical technology providers posted a flurry of press releases detailing new and updated offerings. Parexel, PatientsLikeMe and BBK Worldwide were among the companies to show off their wares at the meeting.

Parexel eyes a $150M share buyback

Parexel International has approved a stock repurchase program of up to $150 million, and the company plans to use its existing cash and credit to buy up its own shares and boost investor value. 

Parexel picks a chief scientist to guide a transition

CRO Parexel International has been working to better unify its disparate service divisions, and now the company has named its first chief scientific officer to oversee its end-to-end offerings.

Parexel zeroes in on adaptive trials with its latest eClinical move

As the industry embraces risk-based clinical trial monitoring, Parexel International is expanding its banner eClinical offering to help sponsors make data-driven decisions in the middle of a study.

Medidata, Parexel jostle for position in risk-based monitoring market

The potential cost savings generated by risk-based monitoring of clinical trials has led some to tip it as a way to significantly streamline pharma's flabby studies. And that potential has lured tech providers, with Medidata and Parexel both advancing their claims on the market this week.

Parexel boosts revenue with eyes on a $1.9B year

CRO giant Parexel is back on the up and up after a brief stumble in the fall, swinging to another profit as new business flows in.

Big Pharma megadeals could spell trouble for CROs

When Big Pharma execs talk up "synergies" to convince shareholders to buy into mergers, they mean, in part, consolidating contractors. And, with all the megadeals rumored and real surfacing over the past week, CROs could be in for a revenue haircut as the drug business realigns.